文献速递肝肾功能剂量调整药物不良反应与药物警戒治疗药物监测与药物基因组学

急性肾病(AKD)期间的药物管理:ADQI XVI 会议报告

Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting.
PubMed 文献 · Br J Clin Pharmacol · 2017-12-01

该报告汇总第16届急性疾病质量倡议(ADQI)共识会议关于急性肾病(AKD)期间药物管理的结论与推荐。专家组采用改良德尔菲法,聚焦主要经肾排泄、具肾毒性、可能改变肾小球功能或代谢物在AKD中蓄积的药物,推荐入院和出院时、AKD诊断和分期变化时及病情变化时进行药物核对,并强调个体化动态监测。

要点

  • AKD诊断、分期变化及病情变化时应进行药物核对,避免过量中毒或剂量不足治疗失败。
  • 评估药物方案需考虑肾毒性、肾内外消除改变、毒性代谢物、药物相互作用及药效学变化。
  • 应动态监测临床特征、肾脏诊断性检测及治疗药物监测以指导用药方案评估。

核心结论

  • AKD不同阶段的药物管理需要个体化方法并频繁重新评估。
  • 需要更多研究以避免药物相关伤害和治疗失败。

研究设计与样本

  • 第16届急性疾病质量倡议(ADQI)共识会议,采用改良德尔菲法达成共识。
  • 专家回顾和评价现有AKD药物管理文献,确定临床实践和未来研究推荐。

主要发现

  • 专家组聚焦四类药物:主要经肾排泄、具肾毒性、可能改变肾小球功能、代谢物在AKD中改变并可能影响其他器官。
  • 推荐在入院和出院时、AKD诊断和AKD分期变化时以及患者病情变化时进行药物核对。

关键数值与推荐

  • 避免药物不良反应的策略应着眼于减少过量给药和肾毒性所致不良事件,以及剂量不足或药物选择错误所致治疗失败。
  • AKD期间药物方案评估或引入药物时应考虑肾毒性潜力、肾和非肾消除改变、毒性代谢物影响、药物相互作用及AKD中药效学改变。
  • 应使用包括重复系列评估临床特征、肾脏诊断性检测和治疗药物监测的动态监测计划来指导药物方案评估。

临床怎么用

  • 在入院、出院、AKD诊断、AKD分期变化及病情变化时执行药物核对。
  • 评估药物方案时综合考虑肾毒性、消除途径改变、毒性代谢物、药物相互作用和药效学变化。
  • 采用动态监测计划,包括重复临床评估、肾脏诊断性检测和治疗药物监测。

局限性

  • 原文未报告具体研究数量、样本量或定量合并结果。
  • 结论基于共识会议而非系统评价或随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To summarize and extend the main conclusions and recommendations relevant to drug management during acute kidney disease (AKD) as agreed at the 16th Acute Disease Quality Initiative (ADQI) consensus conference. METHODS: Using a modified Delphi method to achieve consensus, experts attending the 16th ADQI consensus conference reviewed and appraised the existing literature on drug management during AKD and identified recommendations for clinical practice and future research. The group focussed on drugs with one of the following characteristics: (i) predominant renal excretion; (ii) nephrotoxicity; (iii) potential to alter glomerular function; and (iv) presence of metabolites that are modified in AKD and may affect other organs. RESULTS: We recommend that medication reconciliation should occur at admission and discharge, at AKD diagnosis and change in AKD phase, and when the patient's condition changes. Strategies to avoid adverse drug reactions in AKD should seek to minimize adverse events from overdosing and nephrotoxicity and therapeutic failure from under-dosing or incorrect drug selection. Medication regimen assessment or introduction of medications during the AKD period should consider the nephrotoxic potential, altered renal and nonrenal elimination, the effects of toxic metabolites and drug interactions and altered pharmacodynamics in AKD. A dynamic monitoring plan including repeated serial assessment of clinical features, utilization of renal diagnostic tests and therapeutic drug monitoring should be used to guide medication regimen assessment. CONCLUSIONS: Drug management during different phases of AKD requires an individualized approach and frequent re-assessment. More research is needed to avoid drug associated harm and therapeutic failure.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ostermann M, Chawla LS, Forni LG, et al. Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting. Br J Clin Pharmacol. 2017. PMID: 29023830. doi:10.1111/bcp.13449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。